Welcome to our dedicated page for Nexgel Wt Exp 120126 news (Ticker: NXGLW), a resource for investors and traders seeking the latest updates and insights on Nexgel Wt Exp 120126 stock.
NEXGEL, Inc. (NASDAQ: NXGL, warrants: NXGLW) regularly issues news and regulatory updates that highlight its activities in healthcare, beauty and over-the-counter (OTC) hydrogel products, contract manufacturing, and drug delivery initiatives. This news page aggregates those announcements so readers can review how the company describes its progress, partnerships and financial results over time.
Recent press releases have focused on quarterly financial results, where NEXGEL reports revenue, gross profit, operating expenses, net loss and non-GAAP measures such as EBITDA and Adjusted EBITDA. Management commentary in these releases discusses performance in contract manufacturing and consumer branded products, including references to partnerships with organizations like Cintas and STADA, and to consumer demand for brands such as Silly George within the company’s broader portfolio.
NEXGEL’s news flow also includes strategic and corporate developments. The company announced the spin-off of select drug delivery application assets into NexGelRx, an entity that will focus on prescription (Rx) drug delivery solutions using NEXGEL’s proprietary hydrogel technology. Follow-up news detailed strategic investments into NexGelRx from investors associated with Diesis Holdings, LLC and the appointment of a board observer and advisor with experience in reimbursement strategy and healthcare commercialization.
Other announcements cover capital markets transactions, such as registered direct offerings and concurrent private placements of common stock and warrants, as well as expanded partnerships like the agreement with STADA Arzneimittel AG, which includes non-dilutive capital to support product launches and marketing efforts in North America. NEXGEL also issues notices about upcoming earnings calls, conference presentations, and new investor presentations furnished via Form 8-K.
Investors and observers can use this news feed to follow NEXGEL’s own descriptions of its financial performance, hydrogel-based product initiatives, partnership activity and governance decisions, and to track how the company communicates its strategy and operations over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
NEXGEL reported a 32% year-over-year revenue increase, reaching $2.05 million for 2022, driven by 34.7% growth in contract manufacturing and a 67.0% rise in branded consumer products. By year-end, the company had over $6.6 million in cash and securities, ensuring operational stability through 2025. Despite a slight revenue dip in Q4 2022, NEXGEL launched innovative products like Turfguard and expanded its joint ventures. The gross profit margin improved significantly to approximately 12.5%, a 3,100% increase from the previous year. However, a net loss of $4.75 million was reported for 2022, with expectations of reduced interest expenses in the coming year.
NEXGEL announced it will release its financial results for Q4 and full year 2022 on March 27, 2023, after market close.
The company specializes in high-water-content hydrogel products for healthcare and consumer applications, having developed over 200 unique formulations.
A conference call will follow the earnings release at 4:30 PM ET that day, accessible via live call or webcast. A replay will be available until April 3, 2023.
Investors can find more information on NEXGEL’s Investor Relations website.
NEXGEL, a provider of hydrogel products, has partnered with former lacrosse player Greg Gurenlian to address turf burn injuries through their innovative product, Turfguard. This hydrogel dressing aims to soothe turf burn while protecting athletic wounds, offering athletes a medical-grade solution to pain and infection risk. Gurenlian, with extensive experience in lacrosse, emphasizes the urgency of proper treatment for turf burn issues. Turfguard patches, FDA cleared, maintain a moist wound environment and offer cooling relief, now available for purchase on Amazon.com.
NEXGEL (NASDAQ: NXGL, NXGLW) announced a strategic acquisition of a 50% interest in CG Converting and Packaging, LLC, a joint venture with C.G. Laboratories Inc. This initiative, effective March 1, 2023, aims to enhance capacity, improve margins, and streamline supply chain operations. CG Labs has been a long-time customer and is profitable, making this acquisition beneficial. NEXGEL will invest $500,000 in the JV to upgrade facilities and equipment. The partnership is expected to yield significant synergies, facilitating the onboarding of new customers and combined marketing efforts.